Capital Management, L.P.Ra ... Net Worth

The estimated Net Worth of Capital Management, L.P.Ra ... is at least $115 Million dollars as of 13 March 2020. Capital Ra owns over 6,337,135 units of Satsuma Pharmaceuticals stock worth over $11,962,074 and over the last 11 years Capital sold STSA stock worth over $102,695,404.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Ra STSA stock SEC Form 4 insiders trading

Capital has made over 21 trades of the Satsuma Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Capital bought 6,337,135 units of STSA stock worth $49,999,995 on 13 March 2020.

The largest trade Capital's ever made was buying 6,337,135 units of Satsuma Pharmaceuticals stock on 13 March 2020 worth over $49,999,995. On average, Capital trades about 1,092,544 units every 84 days since 2013. As of 13 March 2020 Capital still owns at least 10,874,613 units of Satsuma Pharmaceuticals stock.

You can see the complete history of Capital Ra stock trades at the bottom of the page.

Insiders trading at Satsuma Pharmaceuticals

Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Complete history of Capital Ra stock trades at G1 Therapeutics Inc, KalVista Pharmaceuticals Inc, Sangamo Therapeutics Inc, Kala Bio, Eidos Therapeutics Inc, Arvinas Inc, and Satsuma Pharmaceuticals

Satsuma Pharmaceuticals executives and stock owners

Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include:

• John Kollins,
  President, Chief Executive Officer, Director
• Tom O'Neil,
  Chief Financial Officer
• Detlef Albrecht,
  Chief Medical Officer
• John A. Kollins,
  Pres, CEO & Director
• Dr. Detlef F. Albrecht,
  Chief Medical Officer
• Thomas P. O'Neil,
  Chief Financial Officer
• Thomas King,
  Independent Director
• Michael Riebe,
  Independent Director
• Elisabeth Sandoval,
  Independent Director
• Ken Takanashi,
  Independent Director
• Rajeev Shah,
  Independent Director
• Thomas Soloway,
  Director
• Rob Janosky,
  Chief Commercial Officer
• Mic Iwashima,
  Vice President & Head of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Alan C. Mendelson J.D.,
  Sec.
• Robert M. Janosky,
  Chief Commercial Officer
• Dr. Shannon Strom Ph.D.,
  VP & Head of Regulatory Affairs
• Robert Schultz,
  VP & Head of CMC
• Mic Iwashima,
  VP & Head of Operations
• Capital Lp Commodore,
  10% owner
• Capital Management, L.P.Ra ...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Thomas P. O'neil,
  Chief Financial Officer
• Capital Management, L.P.Ra ...,
  
• Mutya Harsch,
  Director
• Braden Michael Leonard,
  10% owner
• Nippon Biomedical Laborator...,
  10% owner